Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
ranibizumab (lucentis) (3 trials)
Dissociative Disorders (Phase 3)
Macular Degeneration (Phase 3)
Retinal Detachment (Phase 3)
Wet Macular Degeneration (Phase 3)
Trials (3 total)
Trial APIs (1 total)